Use of early chemotherapy for hormone-sensitive prostate cancer： time for CHAARTED  

作　　者：Jeanny B Aragon-Ching 

机构地区：[1]Clinical Program Director of Genitourinary Cancers,INOVA Dwight and Martha gchar Cancer Institute,8505 Arlington Boulevard, Suite 100, Pairfax, VA,USA.

出　　处：《Asian Journal of Andrology》2016年第3期444-445,共2页亚洲男性学杂志（英文版）

摘　　要：CHAARTED was an ECOG-led phase III trial looking at early chemotherapy with the use of docetaxel in addition to androgen deprivation therapy （ADT） versus ADT alone in hormone-sensitive prostate cancer. The positive results of the trial showing marked improvement in overall survival in those who received chemotherapy with ADT have revolutionized the treatment of metastatic castration-sensitive prostate cancer.CHAARTED was an ECOG-led phase III trial looking at early chemotherapy with the use of docetaxel in addition to androgen deprivation therapy （ADT） versus ADT alone in hormone-sensitive prostate cancer. The positive results of the trial showing marked improvement in overall survival in those who received chemotherapy with ADT have revolutionized the treatment of metastatic castration-sensitive prostate cancer.

分 类 号：TP311.13[自动化与计算机技术—计算机软件与理论] Q78[自动化与计算机技术—计算机科学与技术]